BioPharma Credit PLC

BPCR:LSE

BioPharma Credit PLC

Actions
  • Price (USD)0.8813
  • Today's Change-0.003 / -0.31%
  • Shares traded28.23k
  • 1 Year change+4.66%
  • Beta0.2933
Data delayed at least 20 minutes, as of Nov 22 2024 11:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8612195
Total Receivables, Net202010
Total Inventory------
Prepaid expenses------
Other current assets, total49----
Total current assets155140105
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments1,2011,2241,266
Note receivable - long term------
Other long term assets------
Total assets1,3571,3641,371
LIABILITIES
Accounts payable12202.22
Accrued expenses3.834.104.12
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total01.95--
Total current liabilities16266.34
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total00.260.56
Total liabilities16276.90
SHAREHOLDERS EQUITY
Common stock141414
Additional paid-in capital607607607
Retained earnings (accumulated deficit)720717743
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,3411,3371,364
Total liabilities & shareholders' equity1,3571,3641,371
Total common shares outstanding1,3031,3191,374
Treasury shares - common primary issue71550.06
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.